model updat thought speak
maintain outperform rate increas target price
updat model solid detail
confer call follow call compani eas
concern initi quarterli perform xarelto
darzalex still view pharma busi drive name especi
key product stelara imbruvica newer asset
tremfya erleada howev understand investor desir
addit driver boost compani growth outlook
pharma medic devic price pressur product
xarelto immunolog franchis continu increas
catalyst import upcom pharma catalyst includ verdict
on-going zytiga patent case expect oct head-to-head data
tremfya vs cosentyx psoriasi uptak xarelto compass
indic follow recent fda approv macro factor may
impact stock react earn come day
remain optimist large-cap compani abl meet beat
consensu estim respect quarter
valuat maintain outperform rate rais target price
rel valuat blue sky valuat
grey sky valuat ep estim move
pleas let us know
would like updat compani model
risk primari risk rate target price slowdown
key pharma growth driver disappoint data on-going
clinic trial well unexpect chang drug price
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi
price oct rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
imbruvica darzalex lai franchis market product
compar current base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
imbruvica darzalex lai franchis market product
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
opportun speak member ir team follow
confer call gain addit clariti dynam around certain product
well bake expect go forward
summar compani answer question
 comment drug price specif immunolog sound littl
worrisom intent
tri signal inflect point immun price alway
competit someth think continu see real
chang previou trend
 talk outlook compar also give us
thought outlook
forese sever factor includ strong comp impact
accrual contract sign start continu
biosimilar gener competit also potenti procrit biosimilar
tracleer gener work gener compani
fda develop appropri rem program gener version drug
 clarifi exact amount one-tim impact ex-u
one-tim impact relat accrual retroact reimburs world-wide
growth would without adjust
 clarifi exact amount one-tim impact
xarelto would without adjust prior-quart price
 impact seen patient hit donut hole quarter
quantifi
actual equal donut hole quarterli although year two
ago estim spread adjust one-tim adjust drive
impact xarelto donut hole
 latest court case zytiga forese gener competit
roll year
judg rule stay end octob zytiga patent
protect upheld depend verdict howev stay date pass without
rule patent automat upheld gener vigor defend patent
lose case could also file appeal opposit parti could possibl
liabl damag expect gener competit zytiga
 think impact gener version zytiga would
uptak erleada
erleada use much earlier patient popul uptak would
affect zytiga gener believ revenu possibl erleada close
doubl zytiga
 breakdown sale product quarter
ww sale us sale
 patient receiv product need go treatment
tnf get tremfya cover
patient bio-nav
 think price esketamin given like use differ
seen tradit chronic dose out-pati anti-depress
earli make comment price
 forese licens requir doctor may need order
give patient
need use front health care profession patient self-
administ intranas spray
 expect need addit warn regard side effects/abus
earli comment
 look like vision growth deceler y/i sequenti basi global
vs respect company-
specif vs share shift vs market growth issu highlight
lot one-tim factor throughout year underli growth
rel constant year
summar jnj answer analyst question compani
earn confer call
 guidanc gave year margin around
margin would stand guidanc gave expect
reinvest
 growth ex-zytiga
oper growth market remov zytiga
depend zytiga right wait court rule
zytiga end stay octob go make
specul predict
 price ex-remicad price immunolog market
continu see price pressur immunolog due payer
increas competit amongst compani within key immunolog categori
howev growth driven volum posit compet
continu believ volum expans drive growth go forward
 expect major shift price dynam pharma busi
price front go see continu evolut price
revolut heavili contract categori
 also elabor darzalex trend ex-u
darzalex growth world-wide relat ex-u one-tim
adjust impact growth point
 esketamin sens confid fda approv need
esketamin confid total data believ
robust program regard panel heard back standard
new drug new mechan action team anticip prepar
one
 erleada expect
erleada launch yet report sale
pre-metastat set sinc urologist oncologist prescrib
strong interest anticip type uptak later line
diseas rather think like chronic uptak
 vision grow faster market stock
vision time outperform market
underli growth contact pipelin healthi cadenc
 also orthoped price slightli wors bp across board vs
read anyth fact
spinal market wors dont expect signific shift come
 would defin transform devic busi would
larg deal smaller tuck-in deal done acceler busi back
in-lin market growth
look scale deal invest tuck-in deal us
deal happen goe back strateg fit creat valu sharehold histor
innov compani come intern
 devic growth biosens webster notabl step market
growth
strong combin market procedur continu increas strong execut
well strong balanc geograph growth asia emea north
america cabana data might slight impact noth team call
clear driver
 drug price perspect provid drug price ad
support administr spirit transpar list price
could confus may help patient believ patient
access inform help believ transpar work
 darzalex expect data maia studi expect
top-line press releas
maia file share alreadi
front-lin data us data includ revlimid import
 commentari emerg market
strong growth exampl bric growth
consum step chang growth em grow time
continu expect em grow time overal global busi
 thought zytiga lawsuit
believ holder strong patent furthermor growth even without
zytiga strong brand deliv absorb rule
invalid patent
 darzalex durat therapi track see space
darzalex think complementari car-t weve dose first
patient alreadi move fast still remain signific unmet need
darzalex bcma car-t togeth nice portfolio
 xarelto feedback follow marin command
result esc
xarelto got approv last week cad/pad team
market alreadi cover addit patient us alon
marin work agenc believ good path forward
continu pursu fda go forward
summari jnj result along comparison estim prior report figur
provid figur
us million unless otherwis state
sale
sale
sale
compani data credit suiss estim streetaccount foa consensu
figur cs comparison guidanc
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
good sold
total expens incom
incom tax basi
ep continu op
dilut ep oper
us million unless otherwis state
prepaid expens
loan note payabl
accru rebat return promot
note receiv employe stock ow nership
accumul incom
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
compani mention price
